Big Data, stemming from the vast amount of data collected from connected health devices, social networks or genome sequencing for instance, is currently providing pharmaceutical companies with a wealth of new opportunities. This large scale analysis of healthcare data will undeniably cause an upheaval in the medical and pharmaceutical industry.
Optimisation of clinical trials, personalisation of treatments, patient support, monitoring of compliance, reduction of R&D costs, etc. This new market comes across as extremely promising both from a medical and financial standpoint. The e-health market for instance, estimated at 2.2 to 3 billion Euros between 2014 and 2017, relies heavily on Big Data.
The pharmaceutical industry is already showing an interest in it and will definitely not miss out on the opportunities provided by Mega Data which should allow them to optimise their clinical trials, follow their patients but also avoid scandals resulting from the use of certain drugs.